

# Asymmetric organocatalytic Michael addition of anthrone to enone†

Chunlin Wu, Wenjun Li, Juanjuan Yang, Xinmiao Liang\* and Jinxing Ye\*

Received 7th January 2010, Accepted 4th May 2010

First published as an Advance Article on the web 21st May 2010

DOI: 10.1039/b927421a

Catalyzed by the bifunctional tertiary amino–thiourea organocatalyst derived from epincinchona alkaloid, the asymmetric Michael addition of anthrone to enone was achieved in high yield with excellent enantioselectivity.

## Introduction

As one of the most important approaches to carbon–carbon bond forming, the Michael addition has drawn significant attention in organic chemistry,<sup>1</sup> as well as asymmetric organocatalysis.<sup>2</sup> The past decade has witnessed explosive growth in the field of asymmetric organocatalysis with a catalytic amount of a small organic molecule.<sup>3</sup> Bifunctional organocatalysts bearing tertiary amine and thiourea, which are able to simultaneously bind and activate two reactants, have exhibited enormous potential in a broad range of enantioselective reactions.<sup>4</sup> Up to now, a variety of bifunctional catalysts have been developed for the asymmetric Michael addition of nitroolefins<sup>5</sup> and enones.<sup>6</sup>

As a reactive diene, anthrone has been successfully applied in the Diels–Alder reaction, which makes it a promising synthetic tool for the formation of cyclic compounds.<sup>7</sup> Effective catalytic asymmetric Diels–Alder reactions of phenylmaleimide activated olefin with anthrone have been reported in the presence of chiral Brønsted base.<sup>7i</sup> However, the Michael addition of anthrone with  $\alpha,\beta$ -unsaturated ketone is still a great challenge due to the Diels–Alder reaction byproducts.<sup>8</sup> So we envisioned the corresponding Michael addition could be exclusively produced in good yield and excellent enantioselectivity in the presence of bifunctional organocatalyst.

Herein we presented a catalytic asymmetric Michael addition of anthrone to  $\alpha,\beta$ -unsaturated ketones for the first time with bifunctional catalyst **1c** developed from cinchona alkaloid.<sup>9</sup>


## Results and discussion

In the initial investigation of screening organocatalysts, the Michael addition of anthrone **2a** to  $\alpha,\beta$ -unsaturated ketone **3a** (2.0 equiv) was carried out in toluene (0.5 M) in the presence of tertiary amino–thiourea organocatalysts (**1a–1f**) at room temperature. As illustrated in Table 1, the **1a**-catalyzed reaction afforded 78% conversion with only 39% ee (Entry 1). To our delight, the conversion increased to 91% with 78% ee when **1b**

Engineering Research Centre of Pharmaceutical Process Chemistry, Ministry of Education, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China. E-mail: yejx@ecust.edu.cn, liangxm@ecust.edu.cn

† Electronic supplementary information (ESI) available: General procedure for the synthesis of substrate and chiral catalyst; HPLC analysis of Michael addition products; <sup>1</sup>H and <sup>13</sup>C NMR spectra of Michael addition products. CCDC reference number 764606. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b927421a

Table 1 Screening of catalysts



Entry <sup>a</sup>	Catalyst	Time/h	Conv. <sup>b</sup> (%)	ee <sup>b</sup> (%)
1	<b>1a</b>	24 h	78	–39
2	<b>1b</b>	24 h	91	–78
3	<b>1c</b>	24 h	97	86
4	<b>1d</b>	24 h	97	86
5	<b>1e</b>	24 h	94	–71
6	<b>1f</b>	24 h	99	–78

<sup>a</sup> In each case, the reaction was carried out with **2a** (0.1 mmol), **3a** (0.2 mmol) and catalyst (0.02 mmol) in toluene (0.2 mL). <sup>b</sup> Detected by HPLC analysis on chiral column.

was employed (Entry 2). In order to obtain excellent conversion and enantioselectivity, we next promoted the Michael reaction in the presence of cinchona alkaloid derived tertiary amino–thiourea organocatalysts **1c–1f**, which have exhibited high catalytic activity in the Michael addition of enone. Gratifyingly, the Michael addition of **2a** with **3a** proceeded to 97% conversion with 86% ee with **1c** as the organocatalyst (Entry 3). The same result was observed when the methoxyl group on the quinoline was removed, using **1d** instead of **1c** (Entry 4). However, when the stereo-configuration of organocatalysts (**1c–1d**) was reversed, replacing **1c** and **1d** with **1e** and **1f**, the enantioselectivity decreased to 71% and 78% (Entries 5–6). It also indicated that 9-amino(9-deoxy)epiquinine would be more helpful to control the enantioselectivity. After screening the catalysts, the conclusion was arrived at that the Michael addition of **2a** and **3a** could be efficiently catalyzed by tertiary amino–thiourea organocatalysts **1c** and **1d**. Therefore, we next conducted the Michael addition using **1c** as the bifunctional organocatalyst.

A survey of solvents revealed that the reaction medium played an important role in the Michael addition. The results are

**Table 2** Optimization of Michael addition conditions

Entry <sup>a</sup>	Catalyst	Solvent	Time/h	Conv. <sup>b</sup> (%)	ee <sup>b</sup> (%)
1	<b>1c</b>	Toluene	24 h	97	86
2	<b>1c</b>	MTBE <sup>b</sup>	24 h	97	84
3	<b>1c</b>	CH <sub>2</sub> Cl <sub>2</sub>	24 h	97	76
4	<b>1c</b>	THF	24 h	72	78
5	<b>1c</b>	Acetone	24 h	97	56
6 <sup>c</sup>	<b>1c</b>	Toluene	72 h	17	59
7 <sup>d</sup>	<b>1c</b>	Toluene	24 h	96	89
8 <sup>e</sup>	<b>1c</b>	Toluene	48 h	94	91
9 <sup>f</sup>	<b>1c</b>	Toluene	60 h	89	91
10 <sup>g</sup>	<b>1c</b>	Toluene	120 h	98	89

<sup>a</sup> In each case, the reaction was carried out with **2a** (0.1 mmol), **3a** (0.2 mmol) and catalyst **1c** (0.02 mmol) in solvent (0.2 mL) under room temperature. <sup>b</sup> Detected by HPLC analysis on chiral column. <sup>c</sup> Reaction was carried out at  $-30^{\circ}\text{C}$ . <sup>d</sup> Reaction was carried out with 0.5 mL solvent. <sup>e</sup> Reaction was carried out with 1 mL solvent. <sup>f</sup> Reaction was carried out with 10 mol% catalyst in 1 mL solvent. <sup>g</sup> Reaction was carried out with 5 mol% catalyst in 1 mL solvent. <sup>h</sup> MTBE means methyl *tert*-butyl ether.

summarized in Table 2. Full conversions and excellent ee values were observed in nonpolar solvents, such as toluene and MTBE (Entries 1–2). In contrast, use of dichloromethane, THF or acetone led to a significant decrease in enantioselectivity (Entries 3–5). For THF and acetone, this might be attributed to the hydrogen bonding interaction between catalyst **1c** and the solvents. Screening solvents revealed that toluene was the best medium in terms of conversion and enantioselectivity. Nevertheless, the reaction became sluggish with lower enantioselectivity if the temperature was reduced to  $-30^{\circ}\text{C}$  (Entry 6). Further investigations revealed that improvement of enantioselectivity was observed when the reactions were carried out in 0.2 M and 0.1 M solutions of the substrate. For example, up to 89% ee value was obtained when the reaction took place in 0.5 mL toluene (Entry 7) and the same level of ee value was observed in 1.0 mL toluene with a slight decrease in conversion (Entry 8). Besides, studies demonstrated that as low as 10 mol% **1c** in 0.1 M solution of the substrate afforded the Michael adduct in 89% conversion with 91% ee in prolonged reaction time (Entry 9). Even when the catalyst loading was reduced to 5 mol%, up to 98% of conversion with 89% ee was obtained after 120 h (Entry 10).

After establishing the optimal reaction conditions, the generality of this Michael addition was explored. The representative results are displayed in Table 3. We first carried out the Michael additions of anthrone **2a** to various aryl enones (**3a–3p**). To our great delight, aryl enones bearing electron-withdrawing and donating groups in the *o*-, *m*-, *p*-positions of the aromatic ring all afforded the desired adducts in high yields (74–98%) with excellent enantioselectivities (84–93%) (Entries 1–16). It appeared that the position and the electronic property of the substituent group on the aromatic ring played a limited role in the yields and the enantioselectivities. If a highly sterically hindered substrate such as 1-phenylpent-1-en-3-one (**3q**) was used, up to 81% yield with

**Table 3** The Michael addition of **2** to **3** in the presence of **1c**

Entry <sup>a</sup>	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	adduct	Yield <sup>b</sup> (%)	ee <sup>c</sup> (%)
1	H ( <b>2a</b> )	C <sub>6</sub> H <sub>5</sub> ( <b>3a</b> )	Me	<b>4aa</b>	95	86
2	H ( <b>2a</b> )	2-ClC <sub>6</sub> H <sub>4</sub> ( <b>3b</b> )	Me	<b>4ab</b>	98	91
3	H ( <b>2a</b> )	3-ClC <sub>6</sub> H <sub>4</sub> ( <b>3c</b> )	Me	<b>4ac</b>	97	91
4	H ( <b>2a</b> )	4-ClC <sub>6</sub> H <sub>4</sub> ( <b>3d</b> )	Me	<b>4ad</b>	97	91
5	H ( <b>2a</b> )	2-FC <sub>6</sub> H <sub>4</sub> ( <b>3e</b> )	Me	<b>4ae</b>	97	90
6	H ( <b>2a</b> )	3-FC <sub>6</sub> H <sub>4</sub> ( <b>3f</b> )	Me	<b>4af</b>	97	86
7	H ( <b>2a</b> )	4-FC <sub>6</sub> H <sub>4</sub> ( <b>3g</b> )	Me	<b>4ag</b>	74	87
8	H ( <b>2a</b> )	2-BrC <sub>6</sub> H <sub>4</sub> ( <b>3h</b> )	Me	<b>4ah</b>	97	91
9	H ( <b>2a</b> )	3-BrC <sub>6</sub> H <sub>4</sub> ( <b>3i</b> )	Me	<b>4ai</b>	98	91
10	H ( <b>2a</b> )	4-BrC <sub>6</sub> H <sub>4</sub> ( <b>3j</b> )	Me	<b>4aj</b>	88	90
11	H ( <b>2a</b> )	2-OMeC <sub>6</sub> H <sub>4</sub> ( <b>3k</b> )	Me	<b>4ak</b>	90	90
12	H ( <b>2a</b> )	3-OMeC <sub>6</sub> H <sub>4</sub> ( <b>3l</b> )	Me	<b>4al</b>	80	91
13	H ( <b>2a</b> )	4-OMeC <sub>6</sub> H <sub>4</sub> ( <b>3m</b> )	Me	<b>4am</b>	85	90
14	H ( <b>2a</b> )	2-MeC <sub>6</sub> H <sub>4</sub> ( <b>3n</b> )	Me	<b>4an</b>	83	93
15	H ( <b>2a</b> )	3-MeC <sub>6</sub> H <sub>4</sub> ( <b>3o</b> )	Me	<b>4ao</b>	97	90
16	H ( <b>2a</b> )	4-MeC <sub>6</sub> H <sub>4</sub> ( <b>3p</b> )	Me	<b>4ap</b>	83	84
17	H ( <b>2a</b> )	C <sub>6</sub> H <sub>5</sub> ( <b>3q</b> )	Et	<b>4aq</b>	81	70
18	Cl ( <b>2b</b> )	C <sub>6</sub> H <sub>5</sub> ( <b>3a</b> )	Me	<b>4ba</b>	92	90
19	OH ( <b>2c</b> )	3-BrC <sub>6</sub> H <sub>4</sub> ( <b>3i</b> )	Me	<b>4ci</b>	83	57

<sup>a</sup> In each case, the reaction was carried out with **2** (0.5 mmol), **3** (1.0 mmol) and **1c** (10 mol%) in toluene (2.5 mL) under room temperature for 72 h. <sup>b</sup> Isolated yield. <sup>c</sup> Detected by chiral HPLC analysis on chiral column.

70% ee could still be obtained (Entry 17). Further investigations revealed that the Michael addition of 1,8-dichloroanthracen-9-one (**2b**) to 4-phenylbut-3-en-2-one (**3a**) also proceeded in 92% yield and 90% ee value (Entry 18). However, only 57% ee value was obtained when using 1,8-dihydroxyanthracen-9-one (**2c**) as the nucleophile (Entry 19). This might be attributed to the competitive activation with **3i** of catalyst **1c** and anthrone derivative **2c**. However, less than 30% enantioselectivities were obtained in the Michael addition of anthrone to alkyl enones (not shown in Table 3).

The asymmetric Michael additions of anthrone **2a** to cyclic enones **5** catalyzed by **1c** were also investigated. The results are shown in Table 4. To our delight, the Michael reaction of cyclohex-2-enone (**5a**) with anthrone **2a** afforded the desired adduct **6aa** with 85% yield and 78% ee (Entry 1). However, the Michael addition of


The asymmetric Michael additions of anthrone **2a** to cyclic enones **5** catalyzed by **1c** were also investigated. The results are shown in Table 4. To our delight, the Michael reaction of cyclohex-2-enone (**5a**) with anthrone **2a** afforded the desired adduct **6aa** with 85% yield and 78% ee (Entry 1). However, the Michael addition of

**Table 4** The Michael addition of **2a** to **5** in the presence of **1c**


Entry <sup>a</sup>	n( <b>5</b> )	adduct	yield <sup>b</sup> (%)	ee <sup>c</sup> (%)
1	1 ( <b>5a</b> )	<b>6aa</b>	85	78
2	2 ( <b>5b</b> )	<b>6ab</b>	91	44

<sup>a</sup> In each case, the reaction was carried out with **2** (0.5 mmol), **5** (1.0 mmol) and **1c** (10 mol%) in toluene (2.5 mL) under room temperature for 72 h. <sup>b</sup> Isolated yield. <sup>c</sup> Detected by chiral HPLC analysis on chiral column.

anthrone **2a** to other cyclic enones produced low enantioselectivity. For example, only 44% ee with 91% yield was obtained when cyclohept-2-enone (**5b**) reacted with anthrone **2a** (Entry 2). The absolute configuration of **4ad** was determined to be *S* by X-ray crystal structural analysis (Scheme 1),<sup>†</sup> and a working model of the reaction transition state was proposed based on the stereo-outcome (Scheme 2).



**Scheme 1** X-Ray structure of enantiopure **4ad**. Thermal ellipsoids are shown with 50% ellipsoids.



**Scheme 2** Proposed working model of the reaction transition state.

## Conclusions

In conclusion, a new organocatalytic methodology has been developed for the asymmetric Michael addition of anthrone to enone. This methodology could afford the required Michael adducts in high yields and excellent enantioselectivities with 10 mol% catalyst loading. It is noteworthy that the Michael addition of anthrone to enone has not been reported yet. Further investigations on anthrone chemistry are underway and results from these studies will be presented in the future.

## Experimental

### General methods

Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra and carbon nuclear magnetic resonance (<sup>13</sup>C NMR) spectra were recorded on a Bruker AV-400 spectrometer (400 MHz and 100 MHz). Chemical shifts for protons are reported in parts per million downfield from tetramethylsilane and are referenced to residual protium in the NMR solvent (CDCl<sub>3</sub>; δ 7.26). Chemical shifts for carbon are reported in parts per million downfield from tetramethylsilane and

are referenced to the carbon resonances of the solvent (CDCl<sub>3</sub>; δ 77.16). Data are represented as follows: chemical shift, integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants in Hertz (Hz). Mass spectra (ESI) were measured on a Waters Micromass LCT spectrometer. High performance liquid chromatography (HPLC) was performed on an Agilent 1200 Series chromatographs using a Daicel Chiralpak AS-H column (0.46 cm x 25 cm), Chiralpak IA-H, IC-H column (0.46 cm x 25 cm), and Regis (R, R)-Whelk O1 column (0.46 cm x 25 cm) as noted.

Crystal structure determination of compound of **4ad**: C<sub>24</sub>H<sub>19</sub>ClO<sub>2</sub>, *M* = 374.84; a block crystal (0.20 × 0.15 × 0.10 mm), *T* = 298(2), λ(Mo-Kα) = 0.71073 Å, Orthorhombic, space group: *P*2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, *a* = 12.5855(10) Å, *b* = 14.0795(11) Å, *c* = 21.9701(17) Å, *V* = 3893.0(5) Å<sup>3</sup>, 16570 total reflections, 5543 unique, *R*<sub>int</sub> = 0.0315, *R*<sub>1</sub> = 0.0535 [*I* > 2σ(*I*)], *wR*<sub>2</sub> = 0.1440, min/max residual electron density −0.298/+0.464 e Å<sup>−3</sup>, Flack parameter: 0.04(14).

### General procedure for asymmetric Michael addition

To a solution of α,β-unsaturated ketone **3** (1.0 mmol) and catalyst **1c** (0.05 mmol) in toluene (2.5 mL) was added anthrone **2a** (0.5 mmol). The reaction mixture was stirred at room temperature for 72 h and then the solvent was removed under vacuum. The residue was purified by column chromatography on silica gel to yield the desired addition product.

**(*S*)-9-(3-Oxo-1-phenylbutyl)anthracen-10(9*H*)-one (4aa).** White solid, Mp: 110–112 °C, 95% yield. [α]<sub>D</sub><sup>23</sup> +2.88 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.07 (d, *J* = 7.6 Hz, 1H), 8.01 (d, *J* = 7.6 Hz, 1H), 7.60 (t, *J* = 6.8 Hz, 1H), 7.53–7.49 (m, 1H), 7.47–7.37 (m, 3H), 7.26–7.25 (m, 1H), 7.12 (t, *J* = 7.6 Hz, 1H), 6.98 (t, *J* = 7.6 Hz, 2H), 6.24 (d, *J* = 7.6 Hz, 1H), 4.56–4.55 (m, 1H), 3.81–3.77 (m, 1H), 2.83 (dd, *J* = 7.2, 17.2 Hz, 1H), 2.69 (dd, *J* = 7.6, 17.2 Hz, 1H), 2.08 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.67, 183.97, 143.04, 141.42, 138.07, 134.09, 133.31, 132.21, 131.93, 128.69, 128.62, 128.56, 127.71, 127.47, 127.22, 127.13, 126.89, 126.48, 60.41, 48.34, 44.84, 30.60. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>20</sub>O<sub>2</sub>) require *m/z* 358.1807, found *m/z* 358.1801. 86% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column, λ = 254 nm, n-Hexane: EtOH = 15:1, flow rate = 0.8 mL min<sup>−1</sup>]: 36.0 min (major), 40.3 min (minor).

**(*S*)-9-(1-(2-Chlorophenyl)-3-oxobutyl)anthracen-10(9*H*)-one (4ab).** White solid, Mp: 147–149 °C, 98% yield. [α]<sub>D</sub><sup>24</sup> +19.58 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.22–8.20 (m, 2H), 7.77–7.75 (m, 1H), 7.65 (t, *J* = 7.6 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.44–7.41 (m, 2H), 7.32–7.29 (m, 1H), 7.21–7.18 (m, 1H), 7.01 (t, *J* = 7.2 Hz, 1H), 6.50 (d, *J* = 7.6 Hz, 1H), 6.26 (d, *J* = 7.6 Hz, 1H), 4.66–4.65 (m, 1H), 4.42–4.38 (m, 1H), 2.41 (dd, *J* = 9.6, 17.2 Hz, 1H), 2.32 (dd, *J* = 5.6, 17.2 Hz, 1H), 1.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 205.53, 184.72, 143.02, 140.29, 137.41, 134.82, 133.45, 133.41, 133.02, 131.51, 129.98, 129.92, 129.20, 128.40, 128.37, 127.63, 127.55, 126.98, 126.90, 126.16, 46.17, 45.86, 41.89, 30.06. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>ClO<sub>2</sub>) require *m/z* 392.1417, found *m/z* 392.1399. 91% ee, determined by Chiral HPLC. [Daicel Chiralpak IC-H column, λ = 254 nm, n-Hexane: EtOH = 15:1, flow rate = 0.8 mL min<sup>−1</sup>]: 28.0 min (major), 30.9 min (minor).



**(S)-9-(1-(3-Chlorophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ac).** White solid, Mp: 129–131 °C, 97% yield.  $[\alpha]_{\text{D}}^{23} +11.58$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.12–8.10 (m, 1H), 8.05–8.03 (m, 1H), 7.63–7.60 (m, 1H), 7.55–7.52 (m, 1H), 7.49–7.46 (m, 1H), 7.43–7.40 (m, 2H), 7.27–7.25 (m, 1H), 7.10–7.09 (m, 1H), 6.91 (t, *J* = 8.0 Hz, 1H), 6.18 (s, 1H), 6.12 (d, *J* = 8.0 Hz, 1H), 4.53–4.52 (m, 1H), 3.78–3.74 (m, 1H), 2.82 (dd, *J* = 7.2, 17.6 Hz, 1H), 2.65 (dd, *J* = 7.6, 17.6 Hz, 1H), 2.10 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 206.10, 183.71, 142.64, 140.95, 140.32, 133.98, 133.49, 133.21, 132.38, 132.08, 128.88, 128.83, 128.53, 128.48, 127.60, 127.43, 127.18, 126.97, 126.78, 126.57, 50.01, 48.03, 44.60, 30.60. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>ClO<sub>2</sub>) require *m/z* 392.1417, found *m/z* 392.1402. 91% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 40.3 min (major), 46.4 min (minor).

**(S)-9-(1-(4-Chlorophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ad).** White solid, Mp: 113–115 °C, 97% yield.  $[\alpha]_{\text{D}}^{23} -2.72$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.10 (d, *J* = 8.0 Hz, 1H), 8.05 (d, *J* = 7.6 Hz, 1H), 7.62–7.59 (m, 1H), 7.54–7.50 (m, 1H), 7.47 (t, *J* = 7.2 Hz, 1H), 7.41 (t, *J* = 7.6 Hz, 2H), 7.26–7.24 (m, 1H), 6.98 (m, 1H), 6.96 (m, 1H), 6.20 (m, 1H), 6.18 (m, 1H), 4.52–4.51 (m, 1H), 3.79–3.75 (m, 1H), 2.80 (dd, *J* = 7.2, 17.6 Hz, 1H), 2.64 (dd, *J* = 8.0, 17.6 Hz, 1H), 2.07 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 206.23, 183.85, 142.72, 141.12, 136.86, 133.93, 133.17, 132.96, 132.34, 132.07, 129.90, 128.57, 128.53, 127.86, 127.63, 127.39, 127.07, 126.68, 49.815, 48.10, 44.85, 30.59. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>ClO<sub>2</sub>) require *m/z* 392.1417, found *m/z* 392.1410. 91% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 30 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 55.2 min (major), 66.5 min (minor).

**(S)-9-(1-(2-Fluorophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ae).** White solid, Mp: 94–95 °C, 97% yield.  $[\alpha]_{\text{D}}^{24} +1.28$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.16–8.11 (m, 2H), 7.61 (t, *J* = 7.2 Hz, 1H), 7.55–7.53 (m, 1H), 7.47 (t, *J* = 7.6 Hz, 1H), 7.43–7.41 (m, 2H), 7.21–7.16 (m, 1H), 6.98–6.90 (m, 2H), 6.83 (t, *J* = 7.6 Hz, 1H), 6.19 (t, *J* = 7.2 Hz, 1H), 4.58–4.57 (m, 1H), 4.17–4.13 (m, 1H), 2.63–2.51 (m, 2H), 1.99 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 205.98, 184.35, 162.27, 159.82, 142.19, 141.74, 133.59, 133.14, 132.48, 132.01, 129.43, 129.39, 129.10, 128.91, 128.83, 128.66, 127.60, 127.44, 126.93, 126.78, 126.53, 126.40, 123.47, 123.42, 115.50, 115.27, 47.29, 43.33, 42.80, 30.27. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>FO<sub>2</sub>) require *m/z* 376.1713 found *m/z* 376.1706. 90% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 10.3 min (major), 14.2 min (minor).

**(S)-9-(1-(3-Fluorophenyl)-3-oxobutyl)anthracen-10(9H)-one (4af).** White solid, Mp: 112–114 °C, 97% yield.  $[\alpha]_{\text{D}}^{23} +5.16$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.11 (d, *J* = 7.6 Hz, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.61 (t, *J* = 7.2 Hz, 1H), 7.53 (t, *J* = 7.2 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 1H), 7.43–7.40 (m, 2H), 7.27–7.25 (m, 1H), 6.98–6.93 (m, 1H), 6.84–6.79 (m, 1H), 6.05 (d, *J* = 7.6 Hz, 1H), 5.95–5.92 (m, 1H), 4.55–4.54 (m, 1H), 3.81–3.77 (m, 1H), 2.82 (dd, *J* = 7.2, 17.6 Hz, 1H), 2.66 (dd, *J* = 8.0, 17.6 Hz, 1H), 2.09 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$

(ppm) 206.192, 183.89, 163.31; 160.86, 142.69, 141.06, 140.92; 140.86, 134.00, 133.24, 132.37, 132.07, 129.20; 129.11, 128.49, 128.50, 127.67, 127.43, 127.01, 126.60, 124.38; 124.36, 115.68; 115.46, 114.08; 113.87, 49.99, 48.09, 44.70, 30.59. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>FO<sub>2</sub>) require *m/z* 376.1713, found *m/z* 376.1697. 86% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 11.1 min (major), 14.0 min (minor).

**(S)-9-(1-(4-Fluorophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ag).** White solid, Mp: 142–144 °C, 74% yield.  $[\alpha]_{\text{D}}^{23} +7.18$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.09 (d, *J* = 7.6 Hz, 1H), 6.02 (d, *J* = 7.6 Hz, 1H), 7.60 (t, *J* = 7.2 Hz, 1H), 7.54 (t, *J* = 7.2 Hz, 1H), 7.47 (t, *J* = 7.2 Hz, 1H), 7.42–7.39 (m, 2H), 7.32–7.30 (m, 1H), 6.69–6.64 (m, 2H), 6.17–6.14 (m, 2H), 4.53–4.52 (m, 1H), 3.80–3.75 (m, 1H), 3.50–3.49 (m, 1H), 5.70 (dd, *J* = 7.2, 17.2 Hz, 1H), 2.67 (dd, *J* = 7.6, 17.6 Hz, 1H), 2.09 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 206.43, 183.82, 163.06; 160.61, 143.05, 141.06, 134.07, 133.74; 133.70, 133.23, 132.36, 131.95, 130.15, 130.07, 128.49, 128.50, 127.58, 127.31, 127.01, 126.57, 114.67, 114.46, 49.69, 48.16, 45.28, 30.60. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>FO<sub>2</sub>) require *m/z* 376.1713, found *m/z* 376.1695. 87% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 12.2 min (major), 18.9 min (minor).

**(S)-9-(1-(2-Bromophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ah).** White solid, Mp: 159–161 °C, 97% yield.  $[\alpha]_{\text{D}}^{23} +33.22$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.24–8.21 (m, 2H), 7.85–7.83 (m, 1H), 7.67–7.63 (m, 2H), 7.49 (t, *J* = 7.2 Hz, 1H), 7.43 (t, *J* = 7.2 Hz, 1H), 7.30–7.28 (m, 1H), 7.14–7.10 (m, 1H), 7.08–7.04 (m, 1H), 6.42 (d, *J* = 7.6 Hz, 1H), 6.25–6.23 (m, 1H), 4.68 (m, 1H), 4.39–4.37 (m, 1H), 2.39 (dd, *J* = 10.0, 17.2 Hz, 1H), 2.28 (dd, *J* = 4.2, 17.2 Hz, 1H), 1.84 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 205.48, 184.85, 143.10, 139.95, 138.99, 133.54, 133.47, 133.42, 133.10, 131.40, 130.15, 129.47, 128.74, 128.33, 127.66, 127.60, 127.02, 126.94, 126.76, 125.87, 48.37, 46.10, 41.91, 30.03. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>BrO<sub>2</sub>) require *m/z* 436.0912, found *m/z* 436.0888. 91% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 9.0 min (major), 10.5 min (minor).

**(S)-9-(1-(3-Bromophenyl)-3-oxobutyl)anthracen-10(9H)-one (4ai).** White solid, Mp: 120–121 °C, 98% yield.  $[\alpha]_{\text{D}}^{23} +14.22$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 8.12 (d, *J* = 7.6 Hz, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.56–7.52 (m, 1H), 7.48 (t, *J* = 7.6 Hz, 1H), 7.44–7.40 (m, 2H), 7.27–7.24 (m, 2H), 6.86–6.83 (m, 1H), 6.32 (m, 1H), 6.17–6.15 (d, *J* = 7.6 Hz, 1H), 4.53–4.52 (m, 1H), 3.77–3.73 (m, 1H), 2.82 (dd, *J* = 7.6, 17.6 Hz, 1H), 2.65 (dd, *J* = 7.6, 17.6 Hz, 1H), 2.10 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 206.08, 183.68, 142.61, 140.92, 140.59, 134.00, 133.22, 132.38, 132.07, 131.75, 130.10, 129.16, 128.53, 128.47, 127.69, 127.45, 127.21, 126.99, 126.69, 121.78, 50.03, 48.04, 44.58, 30.62. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>BrO<sub>2</sub>) require *m/z* 436.0912, found *m/z* 436.0906. 91% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column,  $\lambda$  = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 43.0 min (major), 49.8 min (minor).

**(S)-9-(1-(4-Bromophenyl)-3-oxobutyl)anthracen-10(9H)-one (4aj).** White solid, Mp: 132–134 °C, 88% yield.  $[\alpha]_D^{23}$  –4.04 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.11 (d, *J* = 6.8 Hz, 1H), 8.05 (d, *J* = 6.8 Hz, 1H), 7.62–7.58 (m, 1H), 7.54–7.50 (m, 1H), 7.49–7.45 (m, 1H), 7.43–7.39 (m, 2H), 7.23 (d, *J* = 7.6 Hz, 1H), 7.13–7.11 (m, 2H), 6.16–6.14 (m, 2H), 4.51 (d, *J* = 3.6 Hz, 1H), 3.78–3.73 (m, 1H), 2.78 (dd, *J* = 7.2, 17.6 Hz, 1H), 2.63 (dd, *J* = 8.0, 17.2 Hz, 1H), 2.06 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.18, 183.83, 142.64, 141.14, 137.46, 133.88, 133.14, 132.33, 132.10, 130.81, 130.26, 128.59, 128.53, 127.63, 127.39, 127.07, 126.69, 121.09, 49.87, 48.03, 44.73, 30.59. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>24</sub>H<sub>19</sub>BrO<sub>2</sub>) require *m/z* 436.0912, found *m/z* 436.0897. 90% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column, λ = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 13.0 min (major), 16.6 min (minor).

**(S)-9-(1-(2-Methoxyphenyl)-3-oxobutyl)anthracen-10(9H)-one (4ak).** White foamy solid, 90% yield.  $[\alpha]_D^{23}$  –26.46 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.18–8.14 (m, 2H), 7.65–7.60 (m, 2H), 7.48–7.44 (m, 1H), 7.41–7.35 (m, 2H), 7.23–7.20 (m, 1H), 6.83 (d, *J* = 8.4 Hz, 1H), 6.75 (d, *J* = 7.2 Hz, 1H), 6.70 (t, *J* = 7.6 Hz, 1H), 6.21–6.20 (m, 1H), 4.61–4.60 (m, 1H), 4.33–4.29 (m, 1H), 3.74 (s, 3H), 2.47–2.34 (m, 2H), 1.91 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.70, 184.69, 157.11, 143.50, 141.99, 133.46, 133.21, 132.52, 131.47, 129.54, 128.63, 128.37, 128.23, 127.87, 127.27, 127.09, 126.67, 126.61, 119.81, 110.27, 55.30, 46.69, 43.08, 42.37, 30.15. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>3</sub>) require *m/z* 388.1913, found *m/z* 388.1895. 90% ee, determined by Chiral HPLC. [Daicel Chiralpak IA-H column, λ = 254 nm, n-Hexane: EtOH = 15 : 1, 0.8 mL min<sup>-1</sup>]: 16.4 min (major), 18.5 min (minor).

**(S)-9-(1-(3-Methoxyphenyl)-3-oxobutyl)anthracen-10(9H)-one (4al).** White solid, 108–110 °C, 80% yield.  $[\alpha]_D^{23}$  +1.88 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.10 (d, *J* = 7.6 Hz, 1H), 8.06 (d, *J* = 7.6 Hz, 1H), 7.59 (t, *J* = 7.2 Hz, 1H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.48–7.38 (m, 3H), 7.27–7.26 (m, 1H), 6.90 (t, *J* = 7.6 Hz, 1H), 6.6–6.65 (m, 1H), 5.87 (d, *J* = 7.2 Hz, 1H), 5.78 (m, 1H), 4.55–4.54 (m, 1H), 3.78–3.71 (m, 1H), 3.53 (s, 3H), 2.79 (dd, *J* = 7.2, 10.4 Hz, 1H), 2.67 (dd, *J* = 7.6, 9.6 Hz, 1H), 2.07 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.60, 183.93, 158.86, 143.00, 141.44, 139.67, 134.06, 133.31, 132.17, 131.92, 128.66, 128.64, 128.53, 127.43, 127.19, 126.88, 126.48, 120.99, 114.30, 113.00, 55.00, 50.34, 48.25, 44.79, 30.58. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>3</sub>) require *m/z* 388.1913, found *m/z* 388.1895. 91% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column, λ = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 51.5 min (major), 58.9 min (minor).

**(S)-9-(1-(4-Methoxyphenyl)-3-oxobutyl)anthracen-10(9H)-one (4am).** White solid, 78–80 °C, 85% yield.  $[\alpha]_D^{23}$  –3.2 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.10 (d, *J* = 7.6 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.590 (t, *J* = 7.6 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.47–7.42 (m, 2H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.23 (d, *J* = 7.6 Hz, 1H), 6.54–6.52 (m, 2H), 6.18–6.16 (m, 2H), 4.52–4.51 (m, 1H), 3.76–3.73 (m, 1H), 3.71 (s, 3H), 2.76 (dd, *J* = 6.8, 16.8 Hz, 1H), 2.63 (dd, *J* = 8.0, 17.2 Hz, 1H), 2.04 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.93, 183.89, 158.64, 143.11, 141.58, 134.00, 133.25, 132.14, 131.90, 130.05,

129.62, 128.65, 128.55, 127.39, 127.14, 126.90, 126.51, 113.15, 55.12, 49.81, 48.55, 45.12, 30.56. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>3</sub>) require *m/z* 388.1913, found *m/z* 388.1893. 90% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column, λ = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 48.2 min (major), 54.9 min (minor).

**(S)-9-(3-Oxo-1-*o*-tolylbutyl)anthracen-10(9H)-one (4an).** White solid, Mp: 123–125 °C, 83% yield.  $[\alpha]_D^{23}$  –21.28 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.12–8.09 (m, 2H), 7.57–7.53 (m, 1H), 7.47–7.40 (m, 3H), 7.37 (d, *J* = 7.6 Hz, 1H), 7.08–7.04 (m, 2H), 7.01–6.99 (m, 1H), 6.86 (t, *J* = 7.2 Hz, 1H), 6.08 (d, *J* = 7.6 Hz, 1H), 4.43–4.42 (m, 1H), 4.05–4.00 (m, 1H), 2.70–2.58 (m, 2H), 1.94 (s, 3H), 1.92 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.46, 184.41, 142.40, 142.23, 137.33, 137.25, 134.10, 133.36, 132.13, 131.73, 130.41, 129.67, 128.25, 127.69, 127.46, 127.41, 126.93, 126.88, 126.85, 126.17, 48.10, 45.32, 45.27, 30.57, 19.14. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>2</sub>) require *m/z* 372.1964, found *m/z* 372.1964. 93% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column, λ = 254 nm, n-Hexane: EtOH = 8 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 8.4 min (major), 9.6 min (minor).

**(S)-9-(3-Oxo-1-*m*-tolylbutyl)anthracen-10(9H)-one (4ao).** White solid, Mp: 96–98 °C, 97% yield.  $[\alpha]_D^{23}$  +8.54 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.08 (d, *J* = 7.6 Hz, 1H), 8.01 (d, *J* = 7.6 Hz, 1H), 7.59 (t, *J* = 7.2 Hz, 1H), 7.52–7.48 (m, 1H), 7.47–7.43 (m, 2H), 7.39 (t, *J* = 7.2 Hz, 1H), 7.23 (d, *J* = 7.6 Hz, 1H), 6.94–6.92 (m, 1H), 6.86 (t, *J* = 7.6 Hz, 1H), 6.04 (d, *J* = 7.2 Hz, 1H), 6.00 (m, 1H), 4.54–4.53 (m, 1H), 3.77–3.72 (m, 1H), 2.78 (dd, *J* = 7.2, 17.2 Hz, 1H), 2.66 (dd, *J* = 7.6 Hz, 17.2 Hz, 1H), 2.07 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.76, 183.86, 143.05, 141.55, 137.91, 137.16, 134.13, 133.36, 132.11, 131.89, 129.68, 128.68, 128.55, 127.73, 127.55, 127.39, 127.15, 126.76, 126.38, 125.55, 50.34, 48.41, 44.74, 30.60, 21.18. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>2</sub>) require *m/z* 372.1964, found *m/z* 372.1956. 90% ee, determined by HPLC. [Regis (R, R)-Whelk O1 column, λ = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 30.8 min (major), 34.2 min (minor).

**(S)-9-(3-Oxo-1-*p*-tolylbutyl)anthracen-10(9H)-one (4ap).** White foamy solid, 83% yield.  $[\alpha]_D^{23}$  –2.00 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.09 (d, *J* = 7.6 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.59 (t, *J* = 7.6 Hz, 1H), 7.51–7.43 (m, 3H), 7.41–7.37 (m, 1H), 7.22–7.20 (m, 1H), 6.81–6.79 (m, 2H), 6.18–6.16 (m, 2H), 4.53–4.52 (m, 1H), 3.78–3.73 (m, 1H), 2.75 (dd, *J* = 6.8, 17.2 Hz, 1H), 2.64 (dd, *J* = 8.0, 17.2 Hz, 1H), 2.23 (s, 3H), 2.04 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ (ppm) 206.827, 184.101, 142.987, 141.725, 136.713, 135.156, 133.986, 133.271, 132.121, 131.967, 128.718, 128.572, 128.494, 128.457, 127.410, 127.170, 126.933, 126.551, 50.135, 48.490, 44.805, 30.581, 21.037. HRMS: exact mass calculated for [M+NH<sub>4</sub>]<sup>+</sup> (C<sub>25</sub>H<sub>22</sub>O<sub>2</sub>) require *m/z* 372.1964, found *m/z* 372.1953. 84% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column, λ = 254 nm, n-Hexane: EtOH = 15 : 1, flow rate = 0.8 mL min<sup>-1</sup>]: 12.0 min (major), 13.2 min (minor).

**(S)-10-(3-Oxo-1-phenylpentyl)anthracen-9(10H)-one (4aq).** Colourless oil, 81% yield.  $[\alpha]_D^{22}$  –17.12 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 8.09 (d, *J* = 6.0 Hz, 1H), 8.03

(d,  $J = 8.0$  Hz, 1H), 7.62–7.60 (m, 1H), 7.56–7.41 (m, 4H), 7.31 (d,  $J = 7.6$  Hz, 1H), 7.15–7.12 (m, 1H), 6.99 (t,  $J = 7.6$  Hz, 2H), 6.24 (d,  $J = 7.2$  Hz, 2H), 4.59–4.58 (m, 1H), 3.87–3.82 (m, 1H), 2.85 (dd,  $J = 10.0, 17.2$  Hz, 1H), 2.70 (dd,  $J = 10.0, 17.2$  Hz, 1H), 2.41–2.35 (m, 2H), 1.00 (t,  $J = 7.2$  Hz, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 209.43, 184.04, 143.17, 141.48, 138.16, 134.14, 133.33, 132.23, 131.89, 128.72, 128.63, 128.56, 127.70, 127.46, 127.20, 127.11, 126.92, 126.48, 50.33, 48.34, 43.70, 36.60, 7.64. HRMS: exact mass calculated for  $[\text{M}+\text{NH}_4]^+$  ( $\text{C}_{25}\text{H}_{26}\text{NO}_2$ ) require  $m/z$  372.1964, found  $m/z$  372.1954. 70% ee, determined by Chiral HPLC. [Regis (R, R)-Whelk O1 column,  $\lambda = 254$  nm, n-Hexane: EtOH = 15:1, flow rate = 0.8 mL  $\text{min}^{-1}$ ]: 21.2 min (major), 23.4 min (minor).

**(S)-4,5-Dichloro-9-(3-oxo-1-phenylbutyl)anthracen-10(9H)-one (4ba).** White solid, Mp: 139–140 °C, 92% yield.  $[\alpha]_{\text{D}}^{25}$  23.66 ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.40–7.38 (m, 2H), 7.35–7.32 (m, 1H), 7.31–7.28 (m, 1H), 7.20 (t,  $J = 7.6$  Hz, 1H), 7.10 (s,  $J = 7.6$  Hz, 1H), 7.04 (d,  $J = 7.6$  Hz, 1H), 6.48–6.46 (m, 2H), 4.36 (d,  $J = 5.2$  Hz, 1H), 3.63–3.58 (m, 1H), 2.77–2.76 (m, 2H), 2.04 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 206.27, 181.74, 143.30, 142.31, 138.08, 132.82, 132.67, 132.49, 131.55, 131.27, 131.45, 130.41, 128.23, 127.65, 127.07, 126.93, 50.65, 50.09, 45.21, 30.54. HRMS: exact mass calculated for  $[\text{M}+\text{NH}_4]^+$  ( $\text{C}_{24}\text{H}_{18}\text{Cl}_2\text{O}_2$ ) require  $m/z$  426.1028, found  $m/z$  426.1010. 90% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda = 254$  nm, n-Hexane: EtOH = 8:1, flow rate = 0.8 mL  $\text{min}^{-1}$ ]: 12.2 min (major), 17.1 min (minor).

**(S)-10-(1-(3-Bromophenyl)-3-oxobutyl)-1,8-dihydroxyanthracen-9(10H)-one (4ci).** Yellow solid, 152 °C decomposed, 83% yield.  $[\alpha]_{\text{D}}^{25} +5.52$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 11.82 (s, 1H), 11.68 (s, 1H), 7.52–7.47 (m, 2H), 7.27–7.26 (m, 1H), 6.95 (d,  $J = 8.0$  Hz, 1H), 6.90–6.85 (m, 3H), 6.78 (d,  $J = 7.2$  Hz, 1H), 6.30 (m, 1H), 6.14 (d,  $J = 7.6$  Hz, 1H), 4.46–4.45 (m, 1H), 3.64–3.59 (m, 1H), 2.95 (dd,  $J = 8.0, 17.6$  Hz, 1H), 2.69 (dd,  $J = 6.8, 18.0$  Hz, 1H), 2.15 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 206.08, 192.57, 162.38, 161.96, 144.84, 142.18, 140.15, 136.10, 135.33, 131.72, 130.29, 128.99, 127.27, 121.67, 119.39, 119.20, 117.12, 116.80, 116.49, 116.29, 51.12, 48.28, 44.74, 30.64. HRMS: exact mass calculated for  $[\text{M}+\text{NH}_4]^+$  ( $\text{C}_{24}\text{H}_{19}\text{BrO}_4$ ) require  $m/z$  468.0810, found  $m/z$  468.0807. 57% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda = 254$  nm, n-Hexane: EtOH = 8:1, flow rate = 0.8 mL  $\text{min}^{-1}$ ]: 10.7 min (major), 13.4 min (minor).

**(S)-9-(3-Oxocyclohexyl)anthracen-10(9H)-one (6aa).** White solid. Mp: 118–120 °C, 85% yield.  $[\alpha]_{\text{D}}^{25} +4.90$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 8.27–8.24 (m, 2H), 7.62–7.56 (m, 2H), 7.50–7.44 (m, 3H), 7.38–7.36 (m, 1H), 4.20–4.19 (m, 1H), 2.27–2.20 (m, 3H), 2.02–1.97 (m, 1H), 1.94–1.89 (m, 2H), 1.67–1.64 (m, 1H), 1.48–1.36 (m, 1H), 1.11–1.01 (m, 1H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 210.39, 184.97, 142.17, 141.82, 133.38, 133.34, 132.52, 132.49, 128.70, 128.53, 127.51, 127.49, 127.23, 127.07, 48.58, 48.28, 45.08, 40.86, 27.65, 24.75. HRMS: exact mass calculated for  $[\text{M}+\text{NH}_4]^+$  ( $\text{C}_{20}\text{H}_{18}\text{O}_2$ ) require  $m/z$  308.1651, found  $m/z$  308.1644. 78% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda = 254$  nm, n-Hexane: EtOH = 15:1, flow rate = 0.8 mL  $\text{min}^{-1}$ ]: 33.3 min (major), 36.7 min (minor).

**(S)-10-(3-Oxocycloheptyl)anthracen-9(10H)-one (6ab).** White solid, Mp: 227–228 °C, 91% yield.  $[\alpha]_{\text{D}}^{25} -32.88$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 8.30–8.26 (m, 2H), 7.60–7.58 (m, 2H), 7.52–7.44 (m, 4H), 4.32–4.31 (m, 1H), 2.59–2.56 (m, 1H), 2.45–2.30 (m, 3H), 2.21–2.15 (m, 1H), 1.84–1.75 (m, 2H), 1.68–1.64 (m, 1H), 1.37–1.32 (m, 1H), 1.14–1.07 (m, 1H), 0.90–0.82 (m, 1H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 213.94, 185.74, 143.78, 142.41, 134.16, 133.89, 133.37, 133.09, 129.11, 128.99, 128.21, 128.10, 127.98, 127.70, 50.38, 49.12, 46.78, 44.27, 32.96, 29.01, 24.28. HRMS: exact mass calculated for  $[\text{M}+\text{NH}_4]^+$  ( $\text{C}_{21}\text{H}_{24}\text{NO}_2$ ) require  $m/z$  322.1807, found  $m/z$  322.1804. 44% ee, determined by Chiral HPLC. [Daicel Chiralpak AS-H column,  $\lambda = 254$  nm, n-Hexane: EtOH = 15:1, flow rate = 0.8 mL  $\text{min}^{-1}$ ]: 32.5 min (major), 36.9 min (minor).

## Acknowledgements

This work was supported by East China University of Science and Technology, Shanghai Pujiang Program (08PJ1403300), National Natural Science Foundation of China (20902018) and 111 Project (B07023).

## Notes and references

- P. Perlmutter, *Conjugate Addition Reactions in Organic Synthesis*, Pergamon: Oxford, 1992.
- For recent reviews of asymmetric Michael addition reactions, see: (a) E. N. Jacobsen, A. Pfaltz and H. Yamamoto, *Comprehensive Asymmetric Catalysis*, Springer: Berlin, 1999; (b) A. Berkessel and H. Gröger, *Asymmetric Organocatalysis*, Wiley-VCH: Weinheim, Germany, 2004; (c) N. Krause and A. Hoffmann-Röer, *Synthesis*, 2001, 171; (d) O. M. Berner, L. Tedeschi and D. Enders, *Eur. J. Org. Chem.*, 2002, 1877–1894; (e) J. Christoffers and A. Baro, *Angew. Chem., Int. Ed.*, 2003, 42, 1688–1690; (f) S. B. Tsogoeva, *Eur. J. Org. Chem.*, 2007, 1701–1716; (g) D. Almasi, D. A. Alonso and C. Nájera, *Tetrahedron: Asymmetry*, 2007, 18, 299–365.
- Reviews on organocatalysis: (a) 2b; (b) P. I. Dalko, *Enantioselective Organocatalysis*, Wiley-VCH: Weinheim, 2007; (c) P. I. Dalko and L. Moisan, *Angew. Chem., Int. Ed.*, 2001, 40, 3726–3748; (d) P. I. Dalko and L. Moisan, *Angew. Chem., Int. Ed.*, 2004, 43, 5138–5175; (e) K. N. Houk and B. List, *Acc. Chem. Res.*, 2004, 37, 487–631; (f) J. Seayad and B. List, *Org. Biomol. Chem.*, 2005, 3, 719–724; (g) Y. Takemoto, *Org. Biomol. Chem.*, 2005, 3, 4299–4306; (h) Y. Hayashi, *J. Syn. Org. Chem. Jpn.*, 2005, 63, 464; (i) M. S. Taylor and E. N. Jacobsen, *Angew. Chem., Int. Ed.*, 2006, 45, 1520–1543; (j) T. Marcellini, J. H. van Maarseveen and H. Hiemstra, *Angew. Chem., Int. Ed.*, 2006, 45, 7496–7504; (k) C. Palomo and A. Mielgo, *Angew. Chem., Int. Ed.*, 2006, 45, 7876–7880; (l) B. List, *Chem. Commun.*, 2006, 819–824; (m) M. Marigo and K. A. Jørgensen, *Chem. Commun.*, 2006, 2001–2011; (n) P. Kočovský and A. V. Malkov, *Tetrahedron*, 2006, 62, 243–250; (o) S. J. Connon, *Chem.–Eur. J.*, 2006, 12, 5418–5427; (p) A. G. Doyle and E. N. Jacobsen, *Chem. Rev.*, 2007, 107, 5713–5743; (q) M. J. Gaunt, C. C. Johnson, A. McNally and N. T. Vo, *Drug Discovery Today*, 2007, 12, 8–27; (r) A. Dondoni and A. Massi, *Angew. Chem., Int. Ed.*, 2008, 47, 4638–4660; (s) S. J. Connon, *Synlett*, 2009, 354–376.
- (a) T. Okino, Y. Hoashi and Y. Takemoto, *J. Am. Chem. Soc.*, 2003, 125, 12672–12673; (b) T. Okino, S. Nakamura, T. Furukawa and Y. Takemoto, *Org. Lett.*, 2004, 6, 625–627; (c) S. H. McCooey and S. J. Connon, *Angew. Chem., Int. Ed.*, 2005, 44, 6367–6370; (d) A. Berkessel, F. Cleemann and S. Mukherjee, *Angew. Chem., Int. Ed.*, 2005, 44, 7466–7469; (e) T. Okino, Y. Hoashi, T. Furukawa, X. Xu and Y. Takemoto, *J. Am. Chem. Soc.*, 2005, 127, 119–125; (f) B. Vakulya, S. Varga, A. Csámpai and T. Soós, *Org. Lett.*, 2005, 7, 1967–1969; (g) J. Ye, D. J. Dixon and P. S. Hynes, *Chem. Commun.*, 2005, 4481–4483; (h) B. Li, L. Jiang, M. Liu, Y. Chen, L. Ding and Y. Wu, *Synlett*, 2005, 603–606; (i) T. Inokuma, Y. Hoashi and Y. Takemoto, *J. Am. Chem. Soc.*, 2006, 128, 9413–9419; (j) J. Lubkoll and H. Wennemers, *Angew. Chem., Int. Ed.*, 2007, 46, 6841–6844; (k) L. Zu, J. Wang, H. Li, H. Xie, W. Jiang and W. Wang, *J. Am. Chem. Soc.*, 2007, 129, 1036–1037; (l) S. J. Zuend



- and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2007, **129**, 15872–15883; (m) J. Wang, H. Xie, H. Li, L. Zu and W. Wang, *Angew. Chem., Int. Ed.*, 2008, **47**, 4177–4179.
- 5 For selected examples of organocatalyzed asymmetric Michael addition of nitroolefins, see: (a) B. List, P. Pojarliev and H. J. Martin, *Org. Lett.*, 2001, **3**, 2423–2425; (b) T. Ishii, S. Fujioka, Y. Sekiguchi and H. Kotsuki, *J. Am. Chem. Soc.*, 2004, **126**, 9558–9559; (c) H. Li, Y. Wang, L. Tang, F. Wu, X. Liu, C. Guo, B. M. Foxman and Li. Deng, *Angew. Chem., Int. Ed.*, 2005, **44**, 105–108; (d) Y. Hayashi, T. Gotoh, T. Hayashi and M. Shoji, *Angew. Chem., Int. Ed.*, 2005, **44**, 4212–4215; (e) R. P. Herrera, V. Sgarzani, L. Bernardi and A. Ricci, *Angew. Chem., Int. Ed.*, 2005, **44**, 6576–6579; (f) W. Wang, J. Wang and H. Li, *Angew. Chem., Int. Ed.*, 2005, **44**, 1369–1371; (g) C. Wang, Z. Zhang, X. Dong and X. Wu, *Chem. Commun.*, 2008, 1431–1433; (h) Z. Zhang, X. Dong, D. Chen and C. Wang, *Chem.–Eur. J.*, 2008, **14**, 8780–8783; (i) X. Jiang, Y. Zhang, A. S. C. Chan and R. Wang, *Org. Lett.*, 2009, **11**, 153–156; (j) J. Luo, L. Xu, R. A. S. Hay and Y. Lu, *Org. Lett.*, 2009, **11**, 437–440; (k) C. G. Kokotos and G. Kokotos, *Adv. Synth. Catal.*, 2009, **351**, 1355–1362.
- 6 For selected examples of organocatalyzed asymmetric Michael addition of enones, see: (a) M. Yamaguchi, T. Shiraishi and M. Hiram, *J. Org. Chem.*, 1996, **61**, 3520–3530; (b) S. Hanessian and V. Pham, *Org. Lett.*, 2000, 2975–2978; (c) N. Halland, P. S. Aburel and K. A. Jørgensen, *Angew. Chem., Int. Ed.*, 2003, **42**, 661–665; (d) N. Halland, T. Hansen and K. A. Jørgensen, *Angew. Chem., Int. Ed.*, 2003, **42**, 4955–4957; (e) N. Halland, P. S. Aburel and K. A. Jørgensen, *Angew. Chem., Int. Ed.*, 2004, **43**, 1272–1277; (f) A. Prieto, N. Halland and K. A. Jørgensen, *Org. Lett.*, 2005, **7**, 3897–3900; (g) K. R. Knudsen, C. E. T. Mitchell and S. V. Ley, *Chem. Commun.*, 2006, 66–68; (h) J. Xie, W. Chen, R. Li, W. Du, Y. Chen, Y. Wu, J. Zhu and J. Deng, *Angew. Chem., Int. Ed.*, 2007, **46**, 389–392; (i) P. Li, Y. Wang, X. Liang and J. Ye, *Chem. Commun.*, 2008, 3302–3304; (j) P. Ricci, A. Carlone, G. Bartoli, M. Bosco, L. Sambri and P. Melchiorrea, *Adv. Synth. Catal.*, 2008, **350**, 49–53; (k) Z. Jiang, W. Ye, Y. Yang and C. Tan, *Adv. Synth. Catal.*, 2008, **350**, 2345–2351; (l) P. Li, S. Weng, F. Yu, Q. Liu, W. Li, Y. Wang, X. Liang and J. Ye, *Org. Lett.*, 2009, **11**, 753–756.
- 7 For selected papers of anthrone involved in Diels–Alder reaction, see: (a) M. Koerner and B. Rickborn, *J. Org. Chem.*, 1989, **54**, 6–9; (b) O. Riant and H. B. Kagan, *Tetrahedron Lett.*, 1989, **30**, 7403–7406; (c) M. Koerner and B. Rickborn, *J. Org. Chem.*, 1990, **55**, 2662–2672; (d) O. Riant and H. B. Kagan, *Tetrahedron*, 1994, **50**, 4543–4554; (e) K. Tokioka, S. Masuda, T. Fujii, Y. Hata and Y. Yamamoto, *Tetrahedron: Asymmetry*, 1997, **8**, 101–107; (f) K. Uemae, S. Masuda and Y. Yamamoto, *J. Chem. Soc., Perkin Trans. 1*, 2001, 1002–1006; (g) F. Fache and O. Piva, *Tetrahedron Lett.*, 2001, **42**, 5655–5657; (h) R. Harrison and B. Rickborn, *Org. Lett.*, 2002, **4**, 1711–1713; (i) J. Shen, T. T. Nguyen, Y. Goh, W. Ye, X. Fu, J. Xu and C. Tan, *J. Am. Chem. Soc.*, 2006, **128**, 13692–13693; (j) D. Akalay, G. Dürner and M. W. Göbel, *Eur. J. Org. Chem.*, 2008, 2365–2368.
- 8 For selected papers of anthrone involved in Michael addition, see: (a) 7c–7d, 7i; (b) M. Shi, Z. Lei, M. Zhao and J. Shi, *Tetrahedron Lett.*, 2007, **48**, 5743–5746.
- 9 For selected Michael additions using catalyst **1c** as organocatalyst, see: (a) 4c, 4f, 4g, 4h; (b) J. Wang, H. Li, L. S. Zu, W. Jiang, H. Xie, W. H. Duan and W. Wang, *J. Am. Chem. Soc.*, 2006, **128**, 12652–12653.